Literature DB >> 20214051

The efficacy and safety of two fixed combinations: timolol-dorzolamide-brimonidine versus timolol-dorzolamide. A prospective, randomized, double-masked, multi-center, 6-month clinical trial.

Leopoldo Martín Baiza-Durán1, Jaime Alvarez-Delgado, Angélica Yussett Contreras-Rubio, Javier Medrano-Palafox, Anel De Luca-Brown, Homero Casab-Rueda, Marco Antonio Cortés-Gastélum, Miguel Jorge Garcidueñas-Mejía, Pedro Gómez-Bastar, Félix Gil-Carrasco, Curt Hartleben-Matkin, Jesús Jiménez-Román, Miguel Luis Moreno-Marín, José Antonio Paczka-Zapata, Gustavo Velasco-Gallegos, Mario Vergara-Sinta.   

Abstract

We compared the efficacy and safety of a new fixed combination of timolol 0.5%/odorzolamide 20%/brimonidine 0.2% in ophthalmic solution versus a fixed combination of timolol 0.5%/dorzolamide 2% in patients with open-angle glaucoma or ocular hypertension. The fixed triple combination was significantly more efficient in mean intraocular pressure reduction from baseline throughout the six-month follow-up.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 20214051

Source DB:  PubMed          Journal:  Ann Ophthalmol (Skokie)        ISSN： 1530-4086


  6 in total

1.  A 4-year retrospective study of add-on therapy to the fixed combination of dorzolamide/timolol for the treatment of POAG.

Authors:  Curt Hartleben-Matkin; Diddier Prada; Rafael Mancilla-Vences
Journal:  Int J Ophthalmol       Date:  2014-04-18       Impact factor: 1.779

2.  Safety, tolerability, and efficacy of fixed combination therapy with dorzolamide hydrochloride 2% and timolol maleate 0.5% in glaucoma and ocular hypertension.

Authors:  Nicholas P Bell; José L Ramos; Robert M Feldman
Journal:  Clin Ophthalmol       Date:  2010-11-22

3.  Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study.

Authors:  Alfonso García-López; José A Paczka; Jesús Jiménez-Román; Curt Hartleben
Journal:  BMC Ophthalmol       Date:  2014-12-19       Impact factor: 2.209

4.  A Phase III Randomized Clinical Trial of a 0.5% Timolol + 0.2% Brimonidine + 2.0% Dorzolamide Fixed Combination, Preservative-Free Ophthalmic Solution vs. 0.5% Timolol + 0.2% Brimonidine + 2.0% Dorzolamide Fixed Combination in Patients with Controlled Primary Open-Angle Glaucoma.

Authors:  Francisco Gómez-Aguayo; José A Paczka; Rubén Leñero-Córdova; Jesús Jiménez-Román; Jaime Davila-Villarreal; Curt Hartleben; Leopoldo Baiza-Durán; Oscar Olvera-Montaño; Francisco García-Velez; Patricia Muñoz-Villegas
Journal:  Ophthalmol Ther       Date:  2018-04-21

5.  Comparison of timolol 0.5% + brimonidine 0.2% + dorzolamide 2% versus timolol 0.5% + brimonidine 0.2% in a Mexican population with primary open-angle glaucoma or ocular hypertension.

Authors:  Leopoldo Martín Baiza-Durán; Juan Francisco Llamas-Moreno; Clotilde Ayala-Barajas
Journal:  Clin Ophthalmol       Date:  2012-07-11

6.  A Masked, Randomized, Phase 3 Comparison of Triple Fixed-Combination Bimatoprost/Brimonidine/Timolol versus Fixed-Combination Brimonidine/Timolol for Lowering Intraocular Pressure.

Authors:  Curt Hartleben; Juan Camilo Parra; Amy Batoosingh; Paula Bernstein; Margot Goodkin
Journal:  J Ophthalmol       Date:  2017-09-19       Impact factor: 1.909
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.